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Rolf Stahel
With the recognition of the molecular heterogeneity of non-small-cell lung cancer and –importantly– the 
emerging possibilities of personalised therapy for patients 
with advanced disease, biomarker testing in addition to 
conventional pathology has become a central issue. If deci-
sions on personalised therapy now rely on the determina-
tion of biomarkers, then we have to be diligent in providing 
high-quality testing for the community. In order to really 
make an impact for patients, it has become evident that 
closer collaboration and better mutual understanding of the 
respective issues between pathologists and oncologists are 
required. It is in this spirit that the Guidelines for Biomark-
er Testing in advanced non-small cell lung cancer have 
been elaborated jointly by the Spanish Society for Medical 
Oncology and the Spanish Society for Pathology [1].
The ESMO consensus statement elaborated in 2010 
and published the following year recommends EGFR 
somatic mutation testing to identify patients with non-
small-cell lung cancer eligible for fi rst-line treatment with 
an EGFR TKI. Testing should be done in never smokers or 
former light smokers or patients whose tumour has a non-
squamous cell histology [2]. A 2012 update of the ESMO 
consensus statement will also address the issue of ALK 
testing.
The testing of a biomarker alone is important, but so is 
the defi nition of the entire process, from tissue sampling 
until the fi nal reporting of the results, as the clinician uses 
this information to make his decision. This was described 
in a European Workshop for EGFR testing in non-small-
cell lung cancer which took place 2 years ago [3]. In addi-
tion to defi ning a standardised process, timing was felt to 
be of great importance and it was the wish of the partici-
pants that test results be available within one week.
The key challenge for biomarker testing is the avail-
ability of sufficient tissue, as often only small biopsy 
samples are available from patients with metastatic disease. 
This has been addressed by a working group of European 
pathologists who developed algorithms for the diagnostic 
process including immunohistochemistry and molecular 
analysis in small tissue samples [4].
The guidelines for biomarker testing published by the 
Spanish Societies also address the methodologies of EGFR 
testing. It is important to distinguish two principals of 
EGFR testing. The fi rst is screening technologies to detect 
all EGFR mutations, including new mutations. The second 
is targeted technologies to detect specifi c known muta-
tions. The former are currently more widely available, but 
are less sensitive and need more expertise and are more 
labour intensive. The latter are more sensitive and gener-
ally less time consuming, but do not detect all mutations, 
generally need to be processed in batches and are more ex-
pensive. However, with the rapidly evolving technologies 
there will be increasing use of multiplex genotyping giving 
information about several genes of interest [5]. Also, in the 
not too distant future we can expect methods for genomic 
analysis to enter clinical investigation and, later, clinical 
practice [6].
How to best investigate for ALK translocations is a 
matter of ongoing research. Currently the break-apart FISH 
technology is seen as standard. In the future this might be 
complemented by screening with immunohistochemistry 
and multiplex PCR methods.
The National Spanish Consensus statement on bio-
marker testing in advanced non-small-cell lung cancer is a 
great example of how to move forward. The key to success 
will be emphasis on continuous external quality control 
to ensure that the written reports going out the treating 
physicians are reliable, as only then patients can profit 
from personalised therapy [2]. Guidelines the for external 
quality assurance programmes for molecular pathology are 
currently being elaborated in a collaboration between Eu-
ropean Societies and the Italian Medical Oncology Society 
(AIOM). 
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